Our Services

Finding the right acquisition target is harder than closing the deal. We help MedTech companies and PE funds build structured target pipelines based on strategic fit, market positioning, and commercial viability.

Our screening process pairs sector knowledge built over 20+ years in European MedTech with real market intelligence. We go beyond database searches. We tap proprietary networks, assess commercial fundamentals, and deliver shortlists with clear analysis of each target's competitive position, customer base, and growth trajectory. That means fewer months spent chasing the wrong opportunities and a tighter pipeline from the start.

Private equity funds and strategic buyers need more than financial models when evaluating MedTech targets. Our commercial due diligence goes deep on the questions that determine whether a deal will create value: Is the market growing? Is the competitive position defensible? Can the commercial engine scale?

With direct experience managing P&Ls exceeding EUR 210M and integrating acquisitions valued at over EUR 130M, we bring operator perspective to the deal process. We have sat on both sides of the table and understand what makes MedTech businesses succeed or fail post-acquisition.

MedTech is becoming more software-driven, and traditional commercial due diligence misses key questions about digital and AI capabilities. Is the AI clinically validated? Is the data strategy defensible? Can the digital product actually scale commercially?

Our AI & Digital DD evaluates the maturity, scalability, and commercial viability of digital health and AI capabilities within MedTech targets. We assess product-market fit, regulatory readiness (SaMD, MDR), data infrastructure quality, and the realistic path from technology to revenue.

This is not a technology audit. It is a commercial assessment of whether digital and AI capabilities will create value after acquisition, or become expensive distractions. We pair MedTech sector expertise with practical digital health commercialization experience to give investors clarity on what they are actually buying.

We help MedTech companies design and execute commercial strategies that drive measurable growth. Whether you are entering a new European market, launching a new product category, or restructuring your go-to-market model, we bring hands-on experience from leading commercial operations at global MedTech companies.

Our approach pairs rigorous market analysis with practical execution planning. We assess market dynamics, reimbursement landscapes, competitive positioning, and channel strategies to build plans that deliver results, not just reports.

The European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have fundamentally changed the competitive landscape in European MedTech. Companies that treat regulatory compliance as purely a technical exercise miss the strategic implications for portfolio management, market access, and commercial planning.

We help MedTech companies understand and respond to the commercial impact of regulatory change. Our focus is on aligning regulatory strategy with commercial objectives to protect market position and capture new opportunities.

Buy & Build is the dominant value creation play in European MedTech PE. But most platforms struggle with the commercial side. Overlapping product lines, conflicting channel strategies, and customer confusion can destroy value faster than acquisitions create it.

We help PE-backed MedTech platforms plan and execute the commercial dimension of Buy & Build, from defining the acquisition thesis and screening targets to post-deal integration and revenue synergy capture. We have managed the commercial integration of acquisitions exceeding EUR 130M and know what it takes to make acquired businesses perform, not just on paper, but in practice. Each bolt-on is a commercial project, not just a financial transaction.

PE returns in MedTech are increasingly driven by operational value creation, not financial engineering. We work with portfolio company management teams to find and capture commercial value across pricing, channel optimization, market expansion, and product portfolio management.

Our approach comes from running these businesses ourselves. We have managed P&Ls exceeding EUR 210M, driven 27% revenue growth, and expanded market share by 19% in competitive MedTech segments. We bring that experience directly to portfolio companies as embedded advisors who drive results alongside the management team.

We focus on what moves enterprise value: pricing architecture, key account development, geographic expansion, and commercial team effectiveness. Every initiative ties to measurable KPIs and gets tracked through structured review cadences.

Leadership transitions, organizational restructuring, and rapid scaling all require experienced hands at the helm. We provide interim and fractional executive leadership for MedTech companies that need senior commercial expertise without the time or commitment of a permanent hire.

Our interim engagements are not about keeping the seat warm. We drive change, build capability, and deliver results during the engagement period. Every interim assignment comes with a clear mandate, measurable objectives, and a structured handover plan.